Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia

被引：27

作者：

Yoest, Jennifer M. ^{[1
]}

Shirai, Cara Lunn ^{[2
]}

Duncavage, Eric J. ^{[2
]}

机构：

[1] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA

[2] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2020年 / 8卷

关键词：

measurable (minimal) residual disease; acute myeloid leukemia; next generation sequencing; unique molecular identifier; error-corrected sequencing; clinical applications of NGS; AML MRD; QUANTITATIVE RT-PCR; CLONAL HEMATOPOIESIS; TANDEM DUPLICATION; INDUCTION THERAPY; RARE MUTATIONS; DIGITAL PCR; RISK; AML; DIAGNOSIS; TRANSPLANTATION;

D O I：

10.3389/fcell.2020.00249

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.

引用

页数：10

共 50 条

[31] Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia
Juarez-Avendano, Gerardo
Mendez-Ramirez, Nereida
Luna-Silva, Nuria C.
Gomez-Almaguer, David
Pelayo, Rosana
Balandran, Juan C.
BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2021, 78 (03): : 159 - 170
[32] Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
Dix, Caroline
Lo, Tsun-Ho
Clark, Georgina
Abadir, Edward
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 14
[33] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Aitken, Marisa J. L.
Ravandi, Farhad
Patel, Keyur P.
Short, Nicholas J.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[34] Delving the depths of measurable residual disease negativity in acute myeloid leukemia
Freeman, Sylvie D.
HAEMATOLOGICA, 2022, 107 (12) : 2776 - 2778
[35] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Marisa J. L. Aitken
Farhad Ravandi
Keyur P. Patel
Nicholas J. Short
Journal of Hematology & Oncology, 14
[36] Measurable residual disease in pediatric acute myeloid leukemia: a systematic review
Segerink, W. H.
de Haas, V
Kaspers, G. J. L.
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) : 451 - 459
[37] Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
Tettero, Jesse
Heidinga, Maaike
Mocking, Tim
Kelder, Angele
Scholten, Willemijn
Snel, Alexander
Ngai, Lok Lam
Bachas, Costa
van de Loosdrecht, Arjan
Ossenkoppele, Gert
de Leeuw, David
Janssen, Jeroen
Cloos, Jacqueline
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S307 - S308
[38] Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?
Carlsen, Eric D.
Aggarwal, Nidhi
Bailey, Nathanael G.
JOURNAL OF HEMATOPATHOLOGY, 2021, 14 (01) : 3 - 14
[39] Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine
Pratz, Keith W.
Jonas, Brian A.
Pullarkat, Vinod
Recher, Christian
Schuh, Andre C.
Thirman, Michael J.
Garcia, Jacqueline S.
DiNardo, Courtney D.
Vorobyev, Vladimir
Fracchiolla, Nicola S.
Yeh, Su-Peng
Jang, Jun Ho
Ozcan, Muhit
Yamamoto, Kazuhito
Illes, Arpad
Zhou, Ying
Dail, Monique
Chyla, Brenda
Potluri, Jalaja
Doehner, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (08) : 855 - +
[40] Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, Robert P.
Steensma, David P.
Graubert, Timothy A.
Ebert, Benjamin L.
BLOOD, 2020, 135 (20) : 1729 - 1738

← 1 2 3 4 5 →